TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17225620

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 38
Study: 12609560

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day plus CR BNO 1055 (20 mg of herbal drug) for 12 months (intervention group, n=90)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day (usual-care group, n=46)
Number of subjects: 136
Study: 11103179

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 9466128

Group type: EXPERIMENTAL
Intervention: 9 g of fish oil per day
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0 g of fish oil (placebo)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3 g of fish oil per day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil per day
Number of subjects: 58
Study: 8448746

Group type: EXPERIMENTAL
Intervention: UFT (300-400 mg/d for 2 years)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 3008055

Group type: EXPERIMENTAL
Intervention: Methotrexate and citrovorum factor rescue
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 71
Study: 31109001

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (4.8 g) three times a day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27755181

Group type: EXPERIMENTAL
Intervention: LMA‐U
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: LMA‐S
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: I‐gel
Number of subjects: 546
Study: 26486857

Group type: EXPERIMENTAL
Intervention: Customized Short Messaging Service (SMS) reminders for 2 months, including personalized daily medication reminders and twice weekly health information SMS.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Customized Short Messaging Service (SMS) reminders for 2 months.
Number of subjects: 200
Study: 23396493

Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB) using an Eliminate catheter
Number of subjects: 141

Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB)
Number of subjects: 141
Study: 21177789

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg) given subcutaneously once weekly for 3 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: NNC126‐0083
Number of subjects: 33
Study: 19856792

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg) - Itopride (150 mg) fixed dose combination (FDC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12
Study: 17664232

Group type: EXPERIMENTAL
Intervention: ACR neuropsychological battery and Cognitive Symptoms Inventory (CSI)
Number of subjects: 0
Study: 12571611

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 0
Study: 11140307

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study: 8863009

Group type: EXPERIMENTAL
Intervention: Sugar free diet for six months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 32
Study: 1710669

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program for pain control
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 39
Study: 6367859

Group type: EXPERIMENTAL
Intervention: Five drugs (CMFVP)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Three drugs (CMF)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Two scheduling methods of CMFVP
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Non-cross-reacting drug combination
Number of subjects: 772
Study: 4009829

Group type: EXPERIMENTAL
Intervention: Pressure-controlled drainage
Number of subjects: 31

Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 31
Study: 29411270

Group type: EXPERIMENTAL
Intervention: Vitamin E softgel (300 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27874885

Group type: EXPERIMENTAL
Intervention: Azelaic acid (AzA) 15% foam
Number of subjects: 961

Group type: COMPARATOR
Intervention: Vehicle foam (control)
Number of subjects: 961
Study: 24421213

Group type: EXPERIMENTAL
Intervention: Praise
Number of subjects: 59

Group type: COMPARATOR
Intervention: Criticism
Number of subjects: 59
Study: 23242728

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide vaginal suppositories
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlorhexidine digluconate vaginal suppositories
Number of subjects: 50
Study: 20728066

Group type: EXPERIMENTAL
Intervention: 1mg morphine plus 5mg ketamine/bolus (group MK)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2mg/bolus morphine (group MO)
Number of subjects: 46
Study: 18093117

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medical on-treatment review
Number of subjects: 43
Study: 16963789

Group type: EXPERIMENTAL
Intervention: 80% oxygen in air (Group A)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: 40% oxygen in air (Group B)
Number of subjects: 377

Group type: COMPARATOR
Intervention: 40% oxygen in nitrous oxide (Group C)
Number of subjects: 377
Study: 14580054

Group type: EXPERIMENTAL
Intervention: Dolasetron 1.8 mg kg(‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg kg(‐1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10957848

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 28
Study: 8827968

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion at a fixed rate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Blinded comparison of blood samples
Number of subjects: 7
Study: 1487094

Group type: EXPERIMENTAL
Intervention: Five most apical electrodes eliminated from the subject's MAP
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Five most basal electrodes eliminated from subject's MAP
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Middle five electrodes eliminated from subject's MAP
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subject's current MAP
Number of subjects: 5
Study: 6152616

Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 micrograms kg‐1 h‐1 with 66% N2O
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alfentanil at 20 micrograms kg‐1 h‐1 with 66% N2O
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 16
Study: 31149930

Group type: EXPERIMENTAL
Intervention: Pregabalin alone (150 mg preoperatively and twice daily for 14 days)
Number of subjects: 150
Study: 29566463

Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised physical training sessions in a fitness center
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study: 26671006

Group type: EXPERIMENTAL
Intervention: Exogenous testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24834892

Group type: EXPERIMENTAL
Intervention: SpS-SubmSv IRT
Number of subjects: 10

Group type: COMPARATOR
Intervention: SubmSv-FBP
Number of subjects: 10

Group type: COMPARATOR
Intervention: SD-FBP
Number of subjects: 10
Study: 23154549

Group type: EXPERIMENTAL
Intervention: Endostatin treatment (paclitaxel + carboplatin + endostatin)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (paclitaxel + carboplatin + placebo)
Number of subjects: 122
Study: 19937362

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sibutramine plus Metformin (15 mg + 1,700 mg)
Number of subjects: 70
Study: 19114406

Group type: EXPERIMENTAL
Intervention: Test meal (200 g boiled white rice with 50 g natto, 60 g Japanese yams, and 40 g okras)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control meal (200 g white rice with non-viscous boiled soybeans, potatoes, and broccoli)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Test meal vs Control meal
Number of subjects: 11
Study: 16117996

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 100
Study: 12530340

Group type: EXPERIMENTAL
Intervention: Risperidone (daily dosing)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Risperidone (twice daily dosing)
Number of subjects: 18
Study: 10587025

Group type: EXPERIMENTAL
Intervention: Loop excision
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 240
Study: 8905434

Group type: EXPERIMENTAL
Intervention: Pulsating low air‐loss bed
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard non‐pulsating bed
Number of subjects: 16
Study: 1860008

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg/24 h, increased to 100 mg/24 h after 16 months, thiazide added after 30 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 44
Study: 6225482

Group type: EXPERIMENTAL
Intervention: spectinomycin 2 g intramuscularly (group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: cefamandole 1 g intramuscularly after probenecid 1 g orally (group B)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: cefaclor 3 g orally with probenecid 1 g orally (group C)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: cefaclor 3 g orally (group D)
Number of subjects: 400
Study: 31672716

Group type: EXPERIMENTAL
Intervention: Inadequately treated risk conditions
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Inadequately treated risk conditions including lifestyle risk behaviors
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Risk factor control in recurrent events vs first-ever events
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Risk factor control in men vs women
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Risk factor control in patients ≤75 vs >75 years of age
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Estimated degree of stroke preventability for individual risk factors
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Adequate control of the 5 most relevant risk factors combined
Number of subjects: 1730
Study: 28119329

Group type: EXPERIMENTAL
Intervention: Marker chromosomes in patients with adverse-risk karyotypes
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Marker chromosomes presence
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Chromothripsis-positive cases
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Control group of marker chromosome-negative complex aberrant karyotypes
Number of subjects: 1026
Study: 25828362

Group type: EXPERIMENTAL
Intervention: secukinumab 1 × 3 mg/kg on Day 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: secukinumab 1 × 10 mg/kg on Day 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: secukinumab 3 × 10 mg/kg on Days 1, 15 and 29
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 23560618

Group type: EXPERIMENTAL
Intervention: FENO measurement in athletes
Number of subjects: 87

Group type: COMPARATOR
Intervention: FENO measurement in sedentary patients
Number of subjects: 87
Study: 21976574

Group type: EXPERIMENTAL
Intervention: Mass distribution of azithromycin (MDA)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Control group (no MDA)
Number of subjects: 1036
Study: 19487593

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 microg/mm2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 131
Study: 17372773

Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 18
Study: 15050487

Group type: EXPERIMENTAL
Intervention: Fenofibrate (n = 207)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 11734596

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Combined estrogen and progestin use
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Unopposed estrogen use
Number of subjects: 620
Study: 8995082

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted right hemicolectomy (LARHC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORHC)
Number of subjects: 61
Study: 8496512

Group type: EXPERIMENTAL
Intervention: Instructional programme for self-management of asthma
Number of subjects: 23
Study: 3440093

Group type: EXPERIMENTAL
Intervention: Meptazinol (0.7 mg kg‐1 and 1.4 mg kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocine (0.3 mg kg‐1 and 0.6 mg kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 29927893

Group type: EXPERIMENTAL
Intervention: Jaw-repositioning custom-made mouthguard (JCM)
Number of subjects: 0
Study: 29581218

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 1403
Study: 25178454

Group type: EXPERIMENTAL
Intervention: Oesophageal temperature (Toes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gastro-intestinal tract temperature (Tgi)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rectal temperature (Trec)
Number of subjects: 8
Study: 25546163

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 428

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 428
Study: 24011093

Group type: EXPERIMENTAL
Intervention: Presentation delivered by a Teenage Cancer Trust educator in Autumn 2013 (intervention group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving the presentation in Spring 2014 after six-month follow-up measures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 21349890

Group type: EXPERIMENTAL
Intervention: CoreValve (n = 141; 8 subclavian and 133 transfemoral)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Edwards Sapien (n = 187; 99 transfemoral and 88 transapical)
Number of subjects: 328
Study: 19153868

Group type: EXPERIMENTAL
Intervention: Analogy learning
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Explicit learning
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no instruction)
Number of subjects: 27
Study: 17408662

Group type: EXPERIMENTAL
Intervention: SCH 503034 200 mg plus PEG‐IFN‐alpha‐2b
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SCH 503034 400 mg plus PEG‐IFN‐alpha‐2b
Number of subjects: 26

Group type: COMPARATOR
Intervention: SCH 503034 200 mg alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: SCH 503034 400 mg alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b alone
Number of subjects: 26
Study: 15570081

Group type: EXPERIMENTAL
Intervention: Low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Best clinical management
Number of subjects: 83
Study: 11257278

Group type: EXPERIMENTAL
Intervention: Lower plasma bilirubin levels in males (12.5 micromol/l)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Higher serum albumin and lower HDL-C
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Major gene segregation of bilirubin levels
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Decreased bilirubin levels
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Inverse correlation between HDL-C and bilirubin
Number of subjects: 328
Study: 9449146

Group type: EXPERIMENTAL
Intervention: Obesity-counseling skills training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 11
Study: 8852539

Group type: EXPERIMENTAL
Intervention: Lacidipine (4-6 mg once daily)
Number of subjects: 3660

Group type: COMPARATOR
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 3660

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg, titrated to 25 mg if required)
Number of subjects: 3660
Study: 2242077

Group type: EXPERIMENTAL
Intervention: 7.5 mg temazepam
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 15 mg temazepam
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 30 mg temazepam
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Higher dose of temazepam
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Temazepam (all doses)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 346260

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31965772

Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg thrice daily for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Famciclovir 500 mg
Number of subjects: 30
Study: 28056794

Group type: EXPERIMENTAL
Intervention: Mercury concentration in toenails (μg per gram)
Number of subjects: 7477

Group type: EXPERIMENTAL
Intervention: Highest versus lowest quartile of mercury concentration
Number of subjects: 7477

Group type: EXPERIMENTAL
Intervention: Highest versus lowest quartile of mercury concentration within the Mediterranean diet intervention group
Number of subjects: 7477

Group type: COMPARATOR
Intervention: Highest versus lowest quartile of mercury concentration within the control arm of the trial
Number of subjects: 7477

Group type: EXPERIMENTAL
Intervention: Fish consumption and n-3 fatty acids
Number of subjects: 7477
Study: 25825853

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) with polyethylene glycol
Number of subjects: 44

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No MBP)
Number of subjects: 44
Study: 26442364

Group type: EXPERIMENTAL
Intervention: eSMART‐HD (serious game for health)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Screen-based HTN education (attentional control)
Number of subjects: 116
Study: 23497163

Group type: EXPERIMENTAL
Intervention: Health coaching with motivational interviewing and a wide range of activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0
Study: 20624812

Group type: EXPERIMENTAL
Intervention: Short-course intravenous antibiotic treatment (≤3 days)
Number of subjects: 12333

Group type: COMPARATOR
Intervention: Long-course intravenous antibiotic treatment (≥4 days)
Number of subjects: 12333
Study: 18468748

Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus ARB
Number of subjects: 425
Study: 17000967

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study: 12853381

Group type: EXPERIMENTAL
Intervention: C1 inhibitor therapy
Number of subjects: 40
Study: 10928765

Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine emulsion
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.1% cyclosporine emulsion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study: 9481968

Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl citrate via periodontal ligament injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo via periodontal ligament injection
Number of subjects: 20
Study: 7942261

Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiload Cu250 IUD
Number of subjects: 0
Study: 3357006

Group type: EXPERIMENTAL
Intervention: VAC (VCR, 1.5 mg/m2 IV days 1 and 8; CYC, 275 mg/m2 IV days 1 through 5; ACT‐D, 0.45 mg/m2 IV days 1 through 5 every 28 days for three cycles)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: VAC-M (CYC, 150 mg/m2 IM days 1 through 7; VCR, 2.0 mg/m2 IV day 8; ACT‐D, 1.7 mg/m2 IV day 8 every 21 days for four cycles)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High, single-dose ACT‐D
Number of subjects: 70
Study: 29388674

Group type: EXPERIMENTAL
Intervention: Pain self-management intervention plus nurse-led support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving electronic video modules only
Number of subjects: 80
Study: 26873491

Group type: EXPERIMENTAL
Intervention: Adherence to antiretroviral therapy (ART)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Strict dose time instructions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Discrepancy between adherence to dose and dose schedule
Number of subjects: 105
Study: 25717121

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound imaging screening before surgery, 1 day after surgery, and approximately 1 week after surgery.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Doppler ultrasound imaging screening for control participants.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Survey administered to all participants after the scans.
Number of subjects: 100
Study: 23537695

Group type: EXPERIMENTAL
Intervention: Fibular taping with tension
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham taping (tape applied without tension)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both interventions (Fibular taping and Sham taping)
Number of subjects: 23
Study: 21134270

Group type: EXPERIMENTAL
Intervention: Individualized high intensity strength and interval training program plus usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 18207723

Group type: EXPERIMENTAL
Intervention: Adapted evidence-based intervention (Cape Town Women's Health CoOp)
Number of subjects: 112
Study: 16340185

Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106